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Abstract 
 
Bone is a remarkable organ in the way of regulating and adapting to different mechanical loading. 
Any imbalance in the process of regulating and adapting, results in bone diseases such as 
osteoporosis. Since the discovery of P2 receptors in 1970s, research in the field has provided 
tremendous amount of information about the physiological and pathophysiological roles of P2 
receptors in many human diseases. P2 receptors are divided in P2X and P2Y receptors whereas 
seven P2X subunits have been identified (P2X1-7). 
P2X7R gene is highly polymorphic and plays a role in the regulation of osteoblast activity and 
changes in receptor function may affect the osteoblast function in general. Several P2X7R SNPs 
have been associated with increased/decreased risk of fracture and lower/increased BMD in cohort 
studies dependent on whether it is a gain of function mutation or loss of function mutation. 
Therefore we decided to elucidate the role of various mutations in osteoblast function by inducing 
mutations in P2X7R gene and transfect the osteoblastic-like cell line ROS 17/2.8. The expression of 
P2X7R was determined in transfected cells and functional analysis was conducted to investigate the 
cellular effect of two gain of function (GOF) SNPs, H155Y and A348T and a single loss of function 
(LOF) R307Q. Furthermore the effect of these SNPs on gene expression of Runx2 and Sp7 and 
specific bone markers was also investigated. 
Expression of P2X7 mRNA was confirmed by Real-time qPCR and functional analysis revealed 
that A348T increased the receptor function while R307Q decreased the receptor function in 
accordance to exist data. The H155Y SNP showed a minor GOF although not significant. The gene 
expression of Runx2 and Sp7 did not show unambiguous results and the same applies for the bone 
markers.  
Our study is the first in terms of showing that R307Q and A348T SNP in P2X7R in osteoblastic cell 
line have LOF and GOF properties, respectively.  
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Resumé  
 
Knogler er unikke i forhold til regulering og tilpasning til forskellige mekaniske påvirkninger. 
Enhver ubalance i regulering og tilpasnings processen kan udvikle sig til knogle sygdomme som 
osteoporose. Forskning i P2 receptorer, siden opdagelsen i 1970’erne, har medført til en enorm 
viden om fysiologiske og patofysiologiske indvirkninger af disse receptorer i mange sygdomme. P2 
receptorer er opdelt i P2X og P2Y hvoraf der er identificeret 7 undertyper af P2x (P2X1-7). 
P2X7R gen er særdeles polymorft og spiller en rolle i reguleringen af osteoblast aktivitet og 
ændringer i receptor funktion kan generelt have indflydelse på osteoblast funktion. Flere kohorte 
studier har associeret P2X7R polymorfier med øget/nedsat fraktur risiko eller lavere/øget BMD 
afhængig om receptoren er en såkaldt ”gain og function” (GOF) eller ”loss of function” (LOF). For 
at klarlægge udvalgte polymorfiers indflydelse på osteoblast funktion har vi induceret mutationer i 
humant P2X7R og transfekteret i osteoblast-lignende cellelinje ROS 17/2.8. Ekspressionen af 
P2X7R blev undersøgt i transfekteret celler og funktionel analyse blev udført for at undersøge de 
cellulære effekter af to GOF polymorfier, H155Y og A348T samt en enkelt LOF R307Q. Ydermere 
blev effekten af disse polymorfier på gen ekspressionen af Runx2 og Sp7, samt specifikke 
knoglemarkører også undersøgt.  
Ekspressionen af P2X7 mRNA blev bekræftet ved Real-time qPCR og funktionel analyse viste at 
A348T øgede receptor funktion mens R307Q nedsatte receptor funktion i overensstemmelse med de 
eksisterende data. H155Y polymorfi viste GOF, dog ikke signifikant. Gen ekspressionen af Runx2 
og Sp7 viste ingen entydige resultater og det samme gælder for knoglemarkørerne. 
Vores studie er den første som påviser at R307Q og A348T polymorfi henholdsvis har LOF og 
GOF effekter i osteoblast-lignende cellelinje.  
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Abbreviations 
ADP: adenosine 5’-diphosphate 
ALPL: Alkaline phosphatase 
ATP: adenosine 5’-triphosphate 
BGLAP: osteocalcin 
BMD: bone mineral density 
BMP: bone morphogenetic protein 
BMU: bone multicellular unit 
Bz-ATP: 2'(3')-O-(4-Benzoylbenzoyl) adenosine-5'-triphosphate 
[Ca2+]i: intracellular calcium concentration 
cDNA: complementary DNA 
Col-1: Collagen type I 
GOF: Gain of function 
IBSP: Integrin-binding sialoprotein 
LOF: Loss of function 
M-CSF: macrophage colony stimulating factor 
NF-κB: nuclear factor-kappa B 
NFATc1: nuclear factor of activated T-cells 
OPG: osteoprotegerin 
P2X7 receptor: P2X7R 
PGE2: prostaglandin E2 
RANK: (receptor activator of NF-κB) 
RANKL: receptor activator of NF-κB ligand 
RT-PCR: transcription polymerase chain reaction 
Runx2: runt-related transcription factors 
SNP: single nucleotide polymorphism 
SEM: standard error of mean 
TGF-β: transforming growth factor beta 
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Introduction 
 
Bone is a remarkable organ with multiple functions and plays a vital role in the preservation of a 
healthy body.  In order to maintain the healthy stature, adaptation is necessary to adjust to the 
demands the skeleton is subjected to. The regulation of adaptations to physiological influences or 
mechanical forces is mainly controlled by osteoclasts and osteoblasts, independent of each other in 
a process called bone modeling. The modeling process may widen or change axis of bones by 
removing or adding bone to the surfaces in response to biomechanical strain. During bone 
modeling, bone formation and bone resorption are not as tightly combined as in bone remodeling. 
Bone remodeling is a tightly coupled process between osteoclasts and osteoblasts which repeatedly 
carry out resorption of old bone and formation of new bone throughout life (Clarke B., 2008). 
An imbalance in remodeling process typically occurs at menopause with increasing osteoclastic 
resorption activity without an equivalent increase in osteoblastic activity; hence the bone resorption 
is greater than bone formation leading to decreased bone mineral density (BMD) and eventually 
osteoporosis. Osteoporosis is a skeletal disease characterized by low BMD and micro-architectural 
deterioration of bone tissue which leads to an increased risk of fracture (Reginster et al., 2006). 
With increasing life expectancy the number of elderly people with osteoporosis is estimated to 
increase considerably thereby representing one of the most challenging clinical problems at present 
and in the future. The basic treatment of osteoporosis is with bisphosphonate compounds or 
recombinant form of parathyroid hormone (PTH), which respectively decreases the fracture rate and 
increase bone formation (Gallager et al., 2013). The new insight in the remodeling process has 
provided new compounds for the treatment of osteoporosis; however more research is needed to 
elucidate the complex mechanism of bone biology to develop new therapies.  
In recent years several cohort studies have indicated that single nucleotide polymorphisms (SNPs) 
in the P2X7 receptor have effect on the incidence of fracture (Jørgersen et al., 2012). There are 
reports of both gain of function and loss of function depending on the specific point mutation in the 
P2X7 receptor. These studies indicates that a gain of function SNP in the receptor can decreases 
risk fracture and loss of function SNP increases the rate of the risk fracture (Ohlendorff et al., 2007; 
Gartland et al., 2012; Jørgensen et al. 2012; Wesselius et al., 2013).     
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Background 
 
To better understand the basis of the degenerative bone disease such as osteoporosis we need to 
know the basic of bone structure and physiology, as well as molecules and cues that drive the 
skeletal development and regulation. In the following sections a short description of bone structure 
and physiology is described, along with remodeling process and a section with osteoporosis.  
Bone Physiology 
Bone is a hard specialized connective tissue that consists of living cells and mineralized matrix. 
Bone matrix is made up of organic and inorganic portions, whereas the organic portion consists of 
protein fibers, primarily collagen. The inorganic portion is made of hydroxyapatite which contains 
calcium and phosphate. The strength and rigidity of the mineralized matrix give bones the ability to 
carry heavy mechanical loads, and protects vital organs such as heart and brain.  
The fundamental bone structure is composed of cortical and trabecular bone. Cortical bone is dense 
and solid and forms the cortex of bones. Trabecular bone is composed of lattice-like network of 
trabecular plates and rods scattered in the bone marrow compartment. Cortical and trabecular bone 
is composed of osteons (Haversian canals/packets). The Haversian canals are surrounded by 
circular layer of concentric lamellae, canaliculi and lacunae containing osteocytes Bones normally 
widen with aging due to bone formation exceeds the bone resorption on the periosteal surface. 
Cortical remodeling rate increases in aging adults which results in greater cortical porosity hence 
thinning of the cortex (Seeley’s et al., 2011). 
 
Figure 1: The cortex of 
compact bone showing osteon, 
the functional unit of cortical 
bone. The osteon (or 
haversian system) consists of a 
single central canal, its 
content and associated 
concentric lamellae and 
osteocytes.  
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Throughout life bones are renewed to maintain bone strength and calcium homeostasis by a process 
known as remodeling. The remodeling process is governed by two types of cells within the bone 
namely osteoblasts which are bone forming cells and osteoclasts which are bone resorbing cells.  
The osteoclasts are responsible for the resorption of bone minerals and are derived from 
hematopoietic monocyte-macrophage lineage precursor cells. Macrophage colony-stimulating 
factor (M-CSF) is essential for differentiation and proliferation of monocyte-macrophage lineage 
cells into osteoclast in the presence of receptor activator of NF-κB ligand (RANKL). RANKL is a 
homotrimeric transmembrane protein and is typically expressed on osteoblastic and activated T-
cells. The secreted form of protein is derived by either proteolytic cleavage or alternative splicing. 
Membrane-bound RANKL binds directly to the membrane receptor, receptor activator of nuclear 
factor κB (RANK), on the osteoclast surface. The activation of the RANK leads to activation of 
several intracellular signaling pathways resulting in osteoclastogenesis. Osteoblasts express a decoy 
receptor osteoprotegerin (OPG) to prevent RANKL from interacting with RANK (Hadjidakis et al. 
2006; Seeley et al., 2011).     
Mature osteoclast is a large multinucleated cell with abundant mitochondria, numerous lysosomes 
and free ribosomes. One of the most remarkable feature of the osteoclasts are when the plasma 
membrane of the osteoclasts connects with bone matrix, it forms many projections called a ruffled 
border. Osteoclasts pump hydrogen ions across the ruffled border into the resorptive pit, thereby 
producing an acid environment that causes decalcification of the bone matrix. Osteoclasts release 
hydrolytic enzymes such as cathepsin K. Cathepsin K is involved in degradation of type I collagen 
and other non-collagenous proteins which have been demineralized by the acidic environment of 
the resorption pit. Osteoclasts also release tartrate-resistant acid phosphatase, matrix 
metalloproteinase 9 and gelatinase to digest the organic matrix (Seeley et al. 2011; Manolagas 
2000).  
Osteoblasts are bone forming cells which arise from bone marrow progenitors belonging to the 
mesenchymal lineage (Heino et al. 2008). Osteoblast differentiation is a multistep process and 
transcription factors such as, Sox9, Runx2 (runt-related transcription factors/cbfa1) and osterix 
(Osx/SP7) are identified as essential for cell fate decision to become chondrocytes or osteoblasts 
from mesenchymal cells (Marie P.J., 2008).  
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Sox9 is present as the earliest transcription factor in prechondrogenic mesenchymal cells, which 
differentiate into chondrocytes. Runx is another early differentiation factor which plays a 
fundamental role in osteoblast commitment.  
 
In vivo studies with runx2 knockout mice show absence of osteoblasts, while heterozygous mice 
display characteristic skeletal abnormalities which are comparable with the defective human bone 
disorder known as cleidocranial dysplasia (CCD).  Osterix or Sp7 which act downstream of runx2 is 
also an essential transcription factor for osteoblast differentiation thereby bone formation. Osterix 
null mutant mice do not form bone and are unable to express osteoblast specific marker. 
Conditional deletion of osterix in mice shows that osterix is essential for osteoblast differentiation 
and formation of bone in adult bones (Nakashima et al. 2002; Zhou et al. 2010).  
The expression of transcription factors are modified by several hormonal and growth factors, which 
either have a positive or negative influence on the commitment, differentiation and survival of 
osteoblast, thereby bone formation.  
Figure 2:  Schematic representation of osteoblast differentiation and regulation of transcription factors 
which occurs in a multistep process. Expression of osteoblast bone marker as ALP, collagen type I and 
osteopontin is higher in pre-osteoblast and immature osteoblast, while osteocalcin is highly expressed in 
mature osteoblasts (from Marie P.J., 2008). 
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Hormonal factors to be mentioned which effects the transcription factors during osteoblastogenesis 
are parathyroid hormone (PTH), growth hormone, estrogens, glucocorticoids and 1,25-dihydroxy 
vitamin D. They all have a positive effect on bone formation besides long term treatment with 
glucocorticoids (Krishnan et al., 2003).  
Growth factors to be mentioned which control osteoblastogenesis by modifying transcription factors 
are bone morphogenetic proteins (BMPs), growth factor-β (TGF-β), β-catenin and Wnt proteins.  
Osteoblasts synthesize a variety of macromolecules to the bone matrix including type 1 collagen, 
which is part of the matrix structure, and vesicles which concentrate the Ca
2+
 and PO4
3-
, thus 
forming the hydroxyapatite crystals. Osteoblasts also secrete osteocalcin (BGLAP), osteopontin, 
osteonectin, bone sialoprotein (IBSP), proteoglycan I and II. Osteoblasts express a large amount of 
alkaline phosphatase which is anchored to outer surface of plasma membrane and plays a role in 
matrix mineralization. Many of these macromolecules are used as marker for osteoblastic gene 
expression; hence bone formation (Clarke B, 2008). 
As bone formation proceeds, osteoblasts are surrounded by bone matrix and differentiate into 
osteocytes. The osteocytes become less active compared to osteoblasts due to loss of some 
organelles, but they remain in contact with the other osteocytes and osteoblasts by cytoplasmic 
extensions or “dendrites”, which run through a network of canaliculi (Kusuzaki et al., 2000; 
Palumbo et al., 1990).  
Osteocytes are the most abundant cells in the bone matrix and are spaced throughout the 
mineralized bone matrix. Osteocytes have a cellular surface that are more than 100-fold greater than 
the surface of trabecular bone, thus increasing the possibility to receive and transmit signals 
(Marotti et al. 1995). It has long been believed that the osteocytes were inactive and dormant cells 
or had a very little osteolytic process but it is now becoming clear that the osteocytes play an 
essential role in the maintenance of bone homeostasis. The main function of the osteocytes is 
mechanosensing and transduction of mechanical stress into a biological response (Galli et al. 2010). 
Osteocytes are distributed throughout the bone tissue and have the ability to communicate with 
other bone cells though a large network of cellular processes spanning through the bone which are 
connected with osteoblasts and lining cells via gap junctions (Turner et al., 2004; Ali et al., 2011) 
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The Remodeling process and Regulation 
The main functions of remodeling is to preserve the mechanical strength of bone by replacing older, 
micro-fractured bone with newer and stronger bone and maintaining calcium and phosphate 
homeostasis. Remodeling begins before birth and continues until the end of our lives.  
The remodeling process occurs in close collaboration between osteoclast, osteoblast, osteocytes as 
well as osteoblast-derived lining cells and the coordinated actions of these cells is described as 
“Basic Multicellular Unit” (BMU).  
The remodeling process consists of several phases: activation, resorption and formation. The 
activation phase of a remodeling cycle involves recruitment and activation of mononuclear pre-
osteoclast from the circulation to the bone surface, where they merge to multinucleated pre-
osteoclasts. Pre-osteoclasts use integrin αvβ3 to interact with bone matrix by binding to RGD 
(arginine, glycine and asparagine) containing peptides in the matrix proteins (bone sialoprotein, 
osteopontin) to form sealing areas around bone resorbing compartments (Ross et al. 1993). Before 
pre-osteoclastic adhering to matrix proteins, osteoblastic lining cells degrade the non-mineralized 
osteoid that exists between the osteoblastic cell layer and the mineralized bone. Osteoclasts cannot 
bind to non-mineralized matrix and not capable of resorbing non-mineralized bone (Henriksen et 
al., 2009; Clarke B, 2008).  
The activation of pre-osteoclast largely depends on the cells of osteoblast lineage (preosteoblasts, 
mature osteoblasts, osteoblastic lining cells and osteocytes) and a range of local factors released by 
these cells. The osteoblast lineage expression of RANKL and M-CSF is essential for osteoclast 
activation and formation. The increase in expression of these factors leads to an increased pool of 
pre-osteoblast which are stimulated to express fusions proteins leading to fusion of mono-nucleated 
osteoclast to multinucleated preosteoclast. These activated pre-osteoclasts become resorbing 
osteoclasts (Henriksen et al., 2009; Lerner, 2008).  
In the resorption phase the activated osteoclasts forms a ruffled border, where secretion of hydrogen 
ions via H
+
-ATPase proton pump and chloride via chloride channels occurs to the resorbing 
compartment to lower the pH. The low ph dissolves hydroxyapatite along with proteolytic enzymes 
as cathepsin K, matrix metalloproteinase and gelatinase completely degrade the remaining 
demineralized organic matrix resulting in creation of Howship’s lacunae (Lerner, 2006; Henriksen 
et al., 2009).   
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The resorption phase is completed when resorbing osteoclasts undergo apoptosis and replaced by 
mononuclear cells. These cell “clean up” the organic matrix left behind of osteoclasts thereby 
preparing the surface for osteoblasts to begin new bone formation in the lacunae.  
The coupling signals linking the end of resorption phase to the beginning of bone formation are not 
yet fully understood, though several signaling candidates are proposed such as TGF-β, IGF-I, 
BMPs, PDGF or fibroblast growth factor. Probably TGF-β plays the most important role in the 
recruitment and activation of osteoblasts because of the abundance in the bone matrix and the 
inhibitory effect on RANKL.  
 
In the formation phase, bone formation proceeds slowly and lasts much longer than the resorption 
phases. Osteoblasts synthesizes new collagenous organic matrix and regulate mineralization of 
matrix. The mineralized matrix is then covered by osteoid and one cell layer of osteoblastic lining 
cells. Osteoclast formation is suppressed during bone formation most likely through OPG produced 
by osteoblasts (Henriksen et al., 2009).  
The regulation of bone remodeling is reasonable highly regulated both by local factors and 
systemic. Some of the important factors already mentioned RANKL, RANK and M-SCF are 
necessary for osteoclastogenesis.  
Figure 3: Schematic model of bone remodeling process. Initiation of the remodeling process starts with 
recruitment of pre-osteoclasts by osteoblastic lining cells to the bone surface. The activated osteoclasts 
form the resorptive lacunae and commit apoptosis. The mononuclear cells in the lacunae prepare the 
surface for new bone formation by newly activated osteoblast (From Lerner 2006). 
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The three major systemic factors necessary for maintaining mineral homeostatic in bone are PTH, 
vitamin D3 and calcitonin, which control the activity of bone resorbing cells (Lerner, 2006).  
PTH plays a key role in maintaining serum calcium concentration by stimulating bone resorption, 
increasing renal reabsorption of calcium and renal calcitriol (active form of vitamin D/1.25-(OH)2 
vitamin D3) production. PTH and calcitriol increase bone resorption by binding to osteoblasts to 
express more RANKL and inhibits expression of OPG. Calcitriol promotes intestinal calcium and 
phosphate absorption, thereby enhance bone mineralization. Calcitonin mediates loss of the ruffled 
border and terminates osteoclast motility and inhibits proteolytic enzymes secretion from 
osteoclasts. Furthermore osteocalcin inhibits calcium reabsorption in renal tubular cells and 
absorption in intestines (Lawrence G., 1999).    
The intriguing bone remodeling process still reveals additional factors important for regulation of 
bone homeostasis and bone formation, which is crucial for the fact that abnormalities in bone 
remodeling cause a variety of skeletal disorders such as osteoporosis, osteopetrosis, Paget’s disease,  
hyperparathyroidism and rheumatoid arthritis.  
 
Osteoporosis 
Osteoporosis is a skeletal condition characterized by the net loss of bone and deterioration of the 
micro-architecture of the skeleton which results in a decrease in bone density. Ultimately the less 
tensile strength in osteoporotic bone leads to significantly greater susceptibility to fracture. The 
clinical significance of osteoporosis lies in the fractures that occur typically in vertebra, distal radius 
and hip, but the risk of fracture is increased in many other sites when bone density is reduced. There 
are usually no symptoms of osteoporosis until a fracture occurs. Hip fractures in particularly are a 
significant cause of morbidity and mortality in the elderly and have a large economic impact 
(Johnell et al., 2005). In 1990 about 1.26 million new hip fractures occurred worldwide and it is 
estimated to increase to 2.6 million by 2025 and 4.5 million by the year of 2050 (Gullberg et al., 
1997). The overall life time risk for a vertebral, hip or distal radius fracture at the age of 50 has been 
estimated to be 40 % in women and 13 % in men, which is very high (Melton et al., 1992).  
Many of the risk factors associated with osteoporosis exert their effect by disrupting the remodeling 
process.  
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The general risk factors is advanced age, race (Caucasian and Asian ethnicity) female sex, early 
menopause, lack of exercise, smoking, family history, excess alcohol, poor nutrition (low calcium 
or high protein).  
Osteoporosis is divided in primary and secondary osteoporosis. Primary osteoporosis most often 
occurs in postmenopausal women but also related with the normal ageing process.  
Secondary osteoporosis is often caused by corticosteroids most frequently due to medication, but in 
some cases also due to Cushing’s syndrome which is characterized by high level of cortisol.  Other 
disease that can cause secondary osteoporosis is hyperparathyroidism, cystic fibrosis, rheumatoid 
arthritis, immobilization and diabetes type I.  
 
The greatest change in bone remodeling occurs at menopause due to a net negative bone balance as 
bone resorption exceeds bone formation. The increasing number of BMU after menopause perturbs 
the steady state of bone remodeling. Bone formation does not increase proportionally in the 
resorption cavities and this result in reversible loss of bone mass and bone mineral. Postmenopausal 
women exhibit two phases of bone loss; the first is mainly trabecular bone loss and peaks after 4-8 
years after menopause and can be attributed to estrogen deficiency. The second phase exhibits a 
persistent and slower loss of both trabecular and cortical bone due to a decrease in bone formation.   
Since both osteoclast and osteoblast express estrogen receptors it is reasonable to assume that 
estrogen have a direct effect on bone remodeling. Several studies have shown that osteoclast-
specific deletion of estrogen receptor results in decreased trabecular bone mass, partly by reducing 
the osteoclast apoptosis hence increasing the lifespan of osteoclasts. In addition to the inducing 
effect on osteoclasts apoptosis, estrogen inhibits RANKL and thereby impaired osteoclastic 
differentiation and formation. Estrogen also increases the OPG production by osteoblasts. Estrogen 
deficiency has been shown to affect the levels of bone resorbing cytokines such as IL-1, Il-6, M-
CSF and TNF-α in mouse models (Lerner, 2006).  
Both IL-1 and TNF-α enhance the expression of RANKL. Estrogen shows a strong inhibitory effect 
on IL-1 and TNF-α production in bone marrow cells and monocytes, furthermore estrogen suppress 
the production of IL-6 in stromal cells and osteoblasts. Ovariectomized mice also showed an 
enhanced production of the above-mentioned cytokines (Lerner, 2006).  
One study showed that administration of specific blockers of IL-1 and TNF-α to postmenopausal 
women reduced the rise in bone resorption marker about one half of the controls (Khosla et al., 
2012).   
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Estrogen also effects the bone formation by inhibiting osteoblast apoptosis and thereby increases 
the lifespan of osteoblasts (Manolagas, 2000). Oxidative stress marker such as reactive oxygen 
species (ROS) increases due to advancing age. ROS inhibits bone formation by working as an 
antagonist for Wnt signaling pathway and ultimately inhibit osteoblastogenesis.  
A lifestyle modification is recommended as baseline treatment for osteoporosis. Life style 
modifications such as smoke cessation, reduction of alcohol consumption, increased physical 
activity as well as vitamin D and calcium supplementation is necessary to improve the life quality 
of any osteoporotic patient along with the established pharmacological preparations.  
Established pharmacological treatment of osteoporosis is usually divided in anti-resorptive, which 
slow down bone resorption and anabolic agents, which stimulate bone formation. Anti-resorptive 
agents include bisphosphonates, estrogen, selective estrogen modulators (SERM), strontium and 
calcitonin. These agents reduce the intensity of bone remodeling thereby permits more complete 
mineralization giving the bone more strength, but they have no reversal effect on the damaged 
structure of bones (Gallager 2013).  
All these compounds have showed in clinical trials to decrease the fracture risk. Bone anabolic 
agents include PTH and strontium. PTH and strontium produces some reconstruction of bone 
through deposition of new bone tissue. Denosumab is a new therapeutic agent (RANKL antibody), 
which block the activation of osteoclasts hence decreasing the bone resorption. New anti-resorptive 
and anabolic bone therapies to be mentioned in different clinical phases are cathepsin-K, glucagon 
like peptide (GLP-2), OPG, sclerostin neutralizing antibodies and rhBMP (Roux, 2010). 
In summary, osteoporosis is a multifactorial disease which affects an increasing amount of people 
due to the growing population of elderly and the enormous cost to treat osteoporosis necessitates 
elaborating the understanding of molecular mechanisms to treat osteoporosis. Although new 
insights into the molecular mechanism of bone remodeling have given rise to new therapeutic 
agents, new perspectives is required to further understanding of the intriguing bone remodeling.  
In recent years, focus on the genetic variations in the human genome and their role in developing 
osteoporosis have received an increasing attention due to fact that several studies have shown 
association between genetic variations and bone turnover and risk of osteoporosis. In the next 
section an overview of purinergic receptors (P2) role in osteoporosis is stated along with structure 
and function of P2X receptors.  
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P2 receptor  
 
The receptors for extracellular nucleotides such as purines and pyrimidines are classified as P1 and 
P2. P1 receptors are primarily activated by adenosine while P2 receptors are activated by several 
nucleotides including adenosine triphosphate (ATP), adenosine diphosphate (ADP), uridine 
triphosphate (UTP) and uridine diphosphate (UDP). The P2 receptor is further subdivided into P2X 
and P2Y; originally based on the agonist and antagonist selectivity in a range of tissues (Burnstock, 
1985).  Latter on, studies showed that P2X receptors are ligand gated ion channels and P2Y are G-
protein-coupled receptors. 
P2X receptor structure and function 
Seven purinergic receptor subunits, denoted P2X1 to P2X7, and several splice variants of these 
subunits have been identified. P2X subunits proteins are 384 (P2X4) to 595 (P2X7) amino-acid 
long and consist of two transmembrane domains (TM1 and TM2), respectively involved with 
channel gating and lining the pore ion,  connected by a large, glycosylated and cysteine rich 
extracellular loop, containing the ATP binding domain, a short intracellular N-terminal domain and 
an intracellular C-terminal domain of variable length. P2X7 C-terminal domain is significantly 
longer compared to the other P2X C-terminal 
domain. These receptors are organized as trimeric 
homomers and heteromers (P2X1, P2X2, P2X3, 
P2X5) (Nicke et al., 1999; Burnstock, 2007). 
Activation of the channel upon ligand binding 
results in influx/efflux of selective cations such as 
Na
+
, K
+
 and Ca
2+
 which leads to depolarization of 
cells and activation of voltage-gated Ca
2+
 
channels (Browne et al. 2010).  
There are seven genes for P2X receptor subunits. 
P2X4 and P2X7 subunits are among the most 
related pairs in amino acid sequences and the 
genes are located close to the tip of the long arm 
of chromosome 12 (12q24.31) and P2X7 gene 
consist of 13 exons (North, 2002).  
Figure 4: Schematic presentation of P2X7 R, with several 
LOF and GOF SNPs. From Gartland et al. 2012. 
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P2X1 and P2X5 are also close located on the short arm of chromosome 13. The remaining genes are 
located on other chromosomes. The full-length forms of these genes consist of 11-13 exons and 
vary significantly in size (mP2X3:40 kb, hP2X6:12 kb), though sharing a common structure with 
conserved intron/exon boundaries. Many splice variants of the subunits exist.  
The most striking feature of amino acid identity between P2X receptors is the conservation of 10 
cysteine residues on the extracellular loop, which contains ATP binding site and a hydrophobic H5 
region close to the pore vestibule for possible receptor/channel modulation by cations (Burnstock 
2007; Yan Z et al., 2005). Furthermore, all P2X receptors have consensus sequences for asparagine 
N-linked glycosylation, but with varying number of N-linked glycosylation between the P2X 
subunits (2-6 sites). Some of these glycosylation are essential for trafficking for the cell surface as 
removal or prevention of glycosylation by tunicamysin or site-directed mutagenesis results in 
retention of receptors inside the cells (North 2002).  
P2X7 receptor subunits were initially cloned from a rat brain cDNA library and are related 
structurally to the other member of P2X family besides its long intracellular C-terminus tail (200 
aa), which contain multiple protein and lipid interactions motifs and a cysteine-rich amino-acid 
segment. P2X7R is expressed on cells of immune system, glia cells, epithelial cells, fibroblasts, 
osteoblasts and etc. The main features of the P2X7R is that with repeatedly and prolonged exposure 
to high concentrations of agonist it forms large aqueous pores in the plasma membrane, permeable 
to hydrophilic molecules as large as 900 Da and this often leads to cell death. Other distinguished 
features are that it requires higher level of ATP for activation of P2X7R compared to other P2X 
receptors (>100 µM), and 2’,3’-(ben-zoyl-4-benzoyl)-ATP (BzATP) is 10-30 more potent agonist of 
P2X7R than ATP (Caddou et al., 2011).  
The pore formation activity of P2X7R is one of the most studied characteristics. The mechanisms 
behind the increase in permeability attributed to P2X7R activation are described mainly as; a 
prolonged ATP stimulation induces conformational changes in P2X7R and recruitment of new 
P2X7 subunits leading to dilation of the channel and/or ATP stimulation induces conformational 
changes in P2X7R resulting in exposure of the protein motifs which interacts/recruits with other 
channel that are permeable to  larger molecules, e.g. connexins and pannexins protein family 
(Tsukimoto et al., 2005; Pelegrin et al., 2006).  
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Since the scoop of this master thesis is P2X7R the next section primarily focus on studies that 
reveal the understanding and mechanisms of P2X7R involved in bone remodeling and the 
increasing data suggesting the role of P2X7R SNPs in developing osteoporosis. 
 
P2X receptor role in bone remodeling   
Purinergic signaling in the bone regulation has emerged to be an active and promising area of 
research due to the fact that P2 receptors are expressed on osteoblast and osteoclast (Ke et al., 2003, 
Nakamura et al., 2000; Gartland et al., 2001; Orriss et al., 2006). The expression of several P2 
receptors on the osteoblasts makes it difficult to attribute responses to specific P2 receptors because 
of the up and down regulation of P2 receptors during osteoblast differentiation and maturation 
(Orriss et al., 2006).  
Studies with knockout (KO) of P2X7 in mice showed a significant reduction in total and cortical 
bone content, reduced periosteal bone formation and increased trabecular bone resorption. Since 
reduced periosteal bone formation and increased bone resorption resembles the disuse in bone, Li 
and colleagues investigated whether P2X7 are necessary for the proper skeletal response to 
mechanical loading and the results showed a significant reduction in skeletal sensitivity to 
mechanical loading (Ke et al., 2003; Li et al., 2005). Furthermore they investigated the effect of 
fluid shear stress (FSS) on isolated calvarial cells from newborn KO mice and 30 min of FSS 
induced pore formation by uptaking dye YO-PRO in WT cells but not in KO cells. They also 
showed that prostaglandin E2 (PGE2) release was increased significantly after 15-60 min of FSS in 
WT compared to KO calvarial cells. Upon BzATP stimulation a significant release of PGE2 was 
observed in MC3T3-E1 osteoblastic cells compared to control. Evidence exists for PGE2 as bone 
anabolic factor in rat models, exerting its function by increasing bone formation, improve bone 
structure and increase bone mass in rats with and without osteopenia (Jee et al, 1997; Ke et al., 
1998).  
Recent studies have shown that P2X7 stimulation leads to membrane blebbing in calvarial 
osteoblast but not in P2X7 KO mice (Panupinthu et al. 2007). The activation of P2X7R by ATP and 
BzATP leads to stimulation of phospholipase D (PLD) and A2 (PLA2) activity and inhibition of 
PLD and PLA2 suppresses P2X7R-induced blebbing.  
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The role of lysophosphatidic acid (LPA) in membrane blebbing was investigated due to the fact that 
LPA can be produced by the actions of PLD and PLA2.  
Suppression of LPA receptors leads to a decrease ability of both LPA and BzATP to induce 
blebbing, without affecting the pore formation of P2X7R, thus indicating that BzATP induced 
blebbing is through LPA acting on its endogenous receptors on osteoblasts.  
Furthermore inhibition of Rho-associated kinase acting downstream of LPA eliminated blebbing 
induced by LPA and BzATP (Panupinthu et al., 2006). In a more recent study the same authors’ 
shows that activation of P2X7R leads to production of LPA and cyclooxygenase metabolites such 
as prostaglandins. The downstream effect of these metabolites is up-regulation of osteoblast 
markers such as Osterix (SP7) and osteocalcin, which stimulates bone mineralization. The authors 
proposed a P2X7-LPA axis which promotes osteogenesis (Panupinthu et al., 2008). 
 
 
 
 
 
 
 
 
 
Furthermore P2X7R involvement in activation of extracellular signal-regulated kinase (ERK) by 
FSS in osteoblast-like cell. Activation of ERK requires Ca
2+
 dependent ATP release, but full 
activation requires increased intracellular Ca
2+
 and PKC activation. ERK plays an essential role in 
activation of various osteogenic genes such as RUNX2, RANKL, COX2 and c-fos (Liu et al., 2008; 
Okumura et al., 2008).   
Figure 5: Activation of P2X7 by ATP or BzATP results in production of prostaglandin via PLA2 and 
production of LPA via PLD and PLA2. PLA and PG exerts their effect by binding to their receptors on 
the same or neighboring cells to induce expression of bone marker genes leading to differentiation 
and mineralization (from Panupinthu et al., 2008). 
22 
 
It is also shown in that in MC3T3-E1 osteoblast-like cells ATP activation of P2X7R induced 
mineral deposition and that P2X7R stimulates osteogenesis by activation of alkaline phosphatase 
which is thought to play a role in mineralization by hydrolyzing inorganic pyrophosphate (PPi) 
(Nakano et al., 2007; Panupinthu et al., 2008). 
Effects of P2 receptors on osteoclast activity have been investigated; in short low extracellular ATP 
concentration (0.2-2 µM) may enhance osteoclast resorption while high concentration of ATP (200-
2000 µM) by activation of P2X7R may exert an apoptotic effect on osteoclasts (Gartland et al., 
1999; Wesselius et al., 2011).  Furthermore, in P2X7 KO mice the presence of multinucleated 
osteoclasts indicates that the P2X7 receptor is either essential for osteoclast differentiation or fusion 
of osteoclast precursors (Gartland et al., 2003; Ke et al., 2003). 
Taken together, these data suggests that bone mineralization and formation is enhanced via ATP 
activation of P2X7R in osteoblasts. Based on the evidence described above it is likely that 
alterations caused by genetic variation in the function of P2X7R may affect the highly regulated 
bone remodeling process thus impairing the balance between bone formation and bone resorption. 
So far only few studies have implicated association between SNPs in P2 receptors and risk of 
developing osteoporosis. 
  
P2X receptor SNP’s 
P2X7R is highly polymorphic with more than 260 SNPs found in the international HapMap project 
(www.hapmap.org). Currently 12 of these SNPs in P2X7R are non-synonymous altering amino-
acid sequence, and potentially affecting the P2X7R function. Characterization of these 12 functional 
SNPs are primarily carried out by Wiley and colleagues. In short, 5 of these functional SNPs are 
described in the following section since the aim of this master thesis is to investigate the role of 
these specific SNPs in the osteoblast-like cell line (ROS 17/2.8). 
The first described P2X7 SNP at position 1513 (adenosine to cytosine) in exon 13 alters the amino 
acid from glutamic acid to alanine at residue 496 (Glu496Ala, E496A). The position of this SNP is 
located in the intracellular C-termini and studies have showed that amino-shift from glutamic to 
alanine is associated with loss of function in terms of ATP induced pore formation and impaired 
apoptosis in homozygous CC allele (Gu et al., 2001; Wiley et al., 2002). 
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Another loss of function SNP in P2X7R is located at residue 307 in the extracellular loop with in 
exon 9. Substitution in base position 946 (guanine to adenine) leads to alteration of amino acid 
arginine to glutamine at this residue (Arg307Gln, R307Q).  
Cells carrying this specific mutation have shown reduced or absent P2X7R function due to the 
failure of ATP binding to the extracellular domain of the receptor. Furthermore lymphocytes from 
heterozygous subjects for the A allele showed an absent or greatly reduced P2X7R function (Gu et 
al., 2004). 
The first gain of function was described by Cabrini et al. This polymorphism is also located in the 
extracellular domain of the receptor at base position 489, where cytosine is substituted by thymine 
leading to a change from histidine to tyrosine at amino acid position 155 (His155Tyr, H155Y). 
Cabrini et al., observed a significant increase in Ca
2+
 influx in both heterozygous and homozygous 
subjects to T (thymine) in lymphocytes. This observation was confirmed by functional analysis in 
HEK293 cells where 489T mutant cells showed increased Ca
2+
 together with ethidium dye uptake 
(Cabrini et al., 2005).  
Another gain of function was described in 2005 by Cabrini et al., where a base substitution in place 
1068 (guanine to adenine) causes substitution in amino acid sequence from alanine to threonine 
(Ala348Thr, A348T). Roger et al. showed that this SNP in functional analysis in HEK293 
transfected cells caused a significant increase in ion channel function and pore formation. 
The substitution of glutamine with arginine (Q460R, Gln460Arg) at base position 1405 (adenine to 
guanine) is associated with minor loss of function (Cabrini et al., 2005; Roger et al., 2010), but is 
mostly associated in connection with haplotype block consisting of Ala348Thr, Thr357Ser, 
Gln460Arg and Glu496Ala.  
 
Role of P2X7R SNPs in osteoporosis 
The first study relating P2X7R SNPs to an increased fracture risk was reported by Jørgersen group 
(Ohlendorff et al., 2007). They identified presence of three non-synonymous SNPs in P2X7 gene 
(Gln460Arg, Glu496Ala and Ile568Asn) in a cohort of approximately 2000 postmenopausal women 
from Danish Osteoporosis Prevention study (DOPS).  
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BMD of lumbar spine and hip were determined at baseline and after 10 years; showing no 
association between BMD and SNPs in untreated group (without hormone replacement therapy 
(HRT)). The incidence in vertebral fracture was determined after 10 years and a significantly 
increased fracture risk was associated with both Glu496Ala and Ile568Asn.  
In vitro study of osteoclasts from women homozygous for Ala496 showed that these osteoclasts had 
a significantly decreased susceptibility to undergo apoptosis compared to women without the 
variant allele. This observation was also showed in a study from Gu et al. where individuals with 
the CC allele had a decreased apoptotic activity in lymphocytes. 
In a recent cohort study from Jørgensen et al., assigning approximately 2000 postmenopausal 
women from DOPS showed that women heterozygous for Arg307Gln had a 40 % increased rate of 
bone loss after 10 years. Even in the HRT treated group the variant allele of this polymorphism 
showed a significant bone loss compared to individuals with wild-type allele. Furthermore a 
significant association was found between gain of function polymorphism Ala348Thr and fracture 
incidence with a decreased incidence in vertebral fracture of almost 70 % in individuals carrying the 
homozygous allele (AA) compared to wild-type allele (GG) (Jørgensen et al,, 2012). Gartland et al. 
revealed similar results from the Abeerdeen Prospective Osteoporosis Screening Study (APOSS) 
where Arg307Gln polymorphism was significantly associated with low BMD at the lower spine of 
postmenopausal women (Gartland et al., 2012). A more recent Dutch cohort study showed that 
Ala348Thr was associated with increased BMD at lumbar spine. Individuals homozygous for 
Glu496Ala were associated with decreased BMD (Wesselius et al., 2013). 
Although recent studies have indicated association between genetic variations in P2X7R gene to 
increased/decreased bone loss further investigation is needed to fully understand the etiology and 
pathophysiology of the human disease osteoporosis.  
Aims 
The aim of this master thesis was to investigate the cellular effects of 5 P2X7R SNPs on osteoblasts 
function in vitro by inducing specific single mutations in hP2X7R inserted in a pcDNA 3.1
+
 vector. 
ROS 17/2.8 cells were transiently transfected with specific SNPs to investigate the effects of these 
mutations by determining the expression of P2X7R with functional analysis. Furthermore determine 
the expression level of specific transcription factors and bone marker implicated in bone formation.   
25 
 
Principles  
In the following section principles behind major methods applied in this master thesis are 
elucidated: Site-directed mutagenesis, Real time-qPCR, Calcium Assay and Western Blot. 
Site-directed mutagenesis of human P2X7 
Site-directed mutagenesis (SDM) plays an essential role in biological studies to investigate variants 
of gene products in in vitro systems - for example natural variations in the coding regions in a 
general population such as SNPs, deletion and insertions. The most common strategy is to introduce 
mutations in the open reading frame (ORF) of the target gene to evaluate the effects of the 
mutations on protein function by comparing it to a well-defined start gene assigned as “wild-type” 
gene. One of the most favored systems to obtain SDM is QuikChange Site-Directed mutagenesis 
kit. 
QuikChange SDM works by using two synthetic 
oligonucleotide primers containing the desired point 
mutations, each complementary to opposite strand of 
the plasmid and flanking the base to be mutated. The 
extension of the mutagenesis primers by temperature 
cycling and PfuUltra HF DNA polymerase generates a 
mutated plasmid which contains staggered nicks.  
PfuUltra HF DNA polymerase decrease the probability 
of generating random mutations and the use of small 
amount of starting DNA template and use of a low 
number of thermal cycles, increases the mutation 
efficiency. After temperature cycling the products are 
treated with DpnI endonuclease.  
The DpnI endonuclease specifically recognizes the 
methylated and hemi-methylated DNA, hence digest 
the parental DNA and select for specific mutated 
synthesized DNA. The desired mutated DNA is the then transformed in XL-10 Ultracompetent cells 
for nick repair (Instruction manual, catalog #210519). 
Figure 6: Modified from Strategene’s Quikchange Site-
directed- mutagenesis 
(http://2012.igem.org/Team:Calgary/Notebook/Protocol
s/mut-agenesis)   
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Real-time RT-PCR analysis for Quantification of gene expression 
Real-time reverse transcription PCR or real time quantitative polymerase chain reaction (qRT-PCR) 
is a technique which is based on polymerase chain reaction (PCR). It is probably the most powerful 
and sensitive tool for gene expression analysis available today. While End-point qPCR has some 
major limitations, as it is impossible to determine the starting concentration of DNA (either cDNA 
or genomic DNA) due to fact that results can first be collected after the reaction is completed. To 
detect and quantify the final product it is required to run gel electrophoresis which is time 
consuming and not quantitative reliable. In real-time PCR the amount of amplified DNA is detected 
during the course of reaction due to fluorescence probes or dyes. As the targeted PCR products 
increase so does the amount of florescence emitted from the fluorophore and thereby makes it 
possible to measure the amount of PCR product when the reaction is still in the exponential phase. 
The exponential phase makes it possible to find out the starting amount of template. In the initial 
phase the fluorescence signal is weak and it is not possible to differentiate from background signal. 
The fluorescent signal increases exponentially and thereafter the fluorescent signal levels off 
because of the reaction running out of crucial components as primers, dNTPs and polymerase. As 
the amount of template increase during the exponential phase the reaction signal reaches threshold 
(Figure 8). Threshold is defined as level of detection at which a reaction reaches a fluorescent 
intensity above background. In order to calculate the threshold level the baseline needs to be 
defined; as PCR cycles where the signals are accumulating in the initial phase but the fluorescence 
level is beneath the limits of detection of the instrument. Threshold is then calculated as 10 times 
the standard deviation of the average signal of the baseline fluorescent signal level. Any signal 
above threshold cycle is considered as a real signal and used to define threshold cycle (CT). The CT 
is defined as fractional cycle number at which the fluorescent signal is greater than the baseline.  
The CT values are used to calculate the relative expression level of each sample (Livak et al,. 2001; 
Derveaux et al., 2010).  
Two different methods of data-analysis exist for real-time qPCR: absolute quantification and 
relative quantification. Absolute quantification or the correct term standard-curve quantification is 
performed when the absolute quantity of a sample is needed, by relating the PCR signal to a 
standard curve.  
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A serial dilution of a “known sample”, most commonly a plasmid with the gene of interest, is used 
to generate the standard curve. Other options to make a standard curve are to use a cell line with 
known copy number or synthetic oligonucleotides for entire amplicon.  
The relative quantification is probably the most common data analysis method used for DNA 
quantification. The 2
-ΔΔCt
 method is used to calculate the relative changes in gene expression in a 
sample (DNA or cDNA) to a reference sample (endogenous control gene). Several assumptions 
must be made if the calculation of 2
-ΔΔCt
 method to be valid. First the reference gene must be 
expressed constant between the samples and the amplification level of the reference gene and gene 
of interest must be approximately equal. The last assumption is that the reaction is occurring with 
100 % efficiency i.e. in each cycle the amount of product doubles. 
Quantification is done relative by subtracting the ΔCT of the control gene from the ΔCT of gene of 
the interest and thereby yielding ΔΔCT. The ΔΔCT is the exponent of base 2 due to the fact that 
reaction doubles the amount of DNA per cycle. The calculated value from equation 2
-ΔΔCt
 is referred 
to relative quantity (RQ) (Livak et al,. 2001; VanGuilder et al., 2008).  
 
Figure 7: Mathematical basis of 2
-ΔΔCT
 method. This method enables relative quantification (from  
VanGuilder et al., 2008). 
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The two most common detection chemistries in real-time qPCR are TagMan chemistry and SYBR 
Green I dye chemistry. Since TagMan probes are used as detection system only the chemistry 
behind the TagMan probes will be explained. 
Sequence specific TagMan probes consist of a fluorescent reporter attached to the 5
’
-end and a 
nonfluorescent quencher at the 3
’
-end. TagMan probes also contain a minor groove binder (MGB) 
at the 3
’
-end, which raises the melting temperature (Tm) of the probe and enables the design of 
shorter probes.  
As long as the probe is intact and the quencher and fluorescent reporter is in close proximity the 
quencher greatly reduces the fluorescence emitted from the reporter by fluorescence-resonance 
energy transfer (FRET) through space. Following annealing of the primers to the target sequence 
the TagMan probes anneal between these primer sites. As the Tag polymerase extends the primers, 
the probes are hydrolyzed by the 5'-3' exonuclease activity of Tag polymerase. The hydrolysis of 
the probes results in separation of the reporter from the quencher thus a cumulative increase in the 
fluorescent signal and removal of the probe from the strand allows polymerase to continue with 
primer extension. With each cycle additional reporter dye are cleaved with increasing fluorescent 
signal which is proportional to the amount of amplicon produced (From manual Applied 
Biosystems).  
 
Calcium Assay 
The development of sensitive and stable probes to measure intracellular calcium has provided 
scientists with great insight in calcium’s ubiquitous role in cellular processes, in large parts, due to 
the development of fluorescent indicators. Traditional functional assays for ion channel receptors 
have been based on electrophysiology but often not suitable for high throughput screening (HTS). 
One of the most successful assays to measure the increase in intracellular calcium upon receptor 
activation has been Fluorometric Imaging Plate Reader (FLIPR) which detects changes in 
intracellular calcium by monitoring cell permeant ion sensitive fluorescent indicators such as Fura-
2, Fluo-4, Fluo-3 etc. Fura-2 is a high affinity Ca
2+
 indicator with Kd of 145 nm and a radiometric 
dye used widely for quantitative measurement of intracellular Ca
2+
.  
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Fura-2 is a dual excitation dye with a peak absorbance of 340 nm in the Ca
2+
 bound state and a peak 
absorbance of 380nm in Ca
2+
 free state with emission at 510 nm.  
Receptor activation leads to flux of Ca
2+
 into the cytosol, where Ca
2+
 binds to fura-2, thereby 
increasing fluorescent intensity. Fluorescent intensity at 340/510 nm increase proportionally while 
380/510 declines at the same rate as the unbound dye diminish (Figure 8A-B). 
 
 
Fura-2 is membrane impermeable therefore it is engineered with acetoxymethyl (AM) esters to 
make it cell permeant. AM dyes are sufficiently hydrophobic to make Fura-2 membrane permeable. 
Intracellular esterases cleave the AM group and trap the dye inside the cell. In general pluronic F-
127 is added to help disperse the Am linked Fura-2 given the fact that AM is water insoluble dye. 
Dimethylsulfoxide DMSO is also added to dissolve AM-linked Ca
2+
 dyes. To prevent leakage of 
Fura-2 once inside the cell probenecid is added to inhibit anion transporter (Hunt el al., 2013). 
 
 
 
 
Figure 8: A) Fura-2 is excited at 340 nm and 380 nm with emission at 510 nm. B) Calcium bound fura-2 is 
excited at 340/510 nm while unbound fura-2 is excited at 380/510 nm resulting in two identical curve. From 
http://www.moleculardevices.com/Products/Assay-Kits/GPCRs/Fura-2-Calcium.html. 
 
A 
B 
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Western blot 
Western blot analysis is a powerful and broadly used method for immune-detection of proteins, 
particularly for detecting of less abundant proteins. In western blot proteins are denatured and 
separated in sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis and transferred to an 
adsorbent membrane (nitrocellulose or PVDF membrane). The blotted proteins form an exact 
replica of the gel and the subsequent incubation with the desired primary antibody and then 
incubation with a secondary antibody conjugated to an enzyme (alkaline phosphatases or horse 
radish peroxidase) binds to primary antibody. Color development after substrate addition occurs and 
sample can be detected by commercially detection systems (Kurien et al., 2006). 
 
 
 
 
Figure 9: Schematic presentation of  principle of immunoblotting. From Kurien et al., 2006. 
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Materials and Methods 
Cell culturing 
The experiments in this study are based on a rat osteosarcoma derived cell-line with osteoblastic 
properties ROS-17/2.8 (ROS). Cells were passaged 2-3 times a week in with trypsin-EDTA 
(Invitrogen) and cultured with Dulbeccos modified Eagle medium containing 1% glutamax 
(DMEM; Invirogen), supplemented with 10% heat inactivated fetal calf bovine serum (FCS; 
Sigma), 1 % penicillin/streptomycin (10.000 U/ml-10.000µg/ml, Life Technologies) and 1 % L-
glutamine. Cells were either cultured in T75 culture flask, 6cm dishes or 96-well plates depending 
on the planned experiments. Cells were kept at 37 °C with 5 % CO2.  
 
Site directed Mutagenesis 
Procedure: 
The site-directed mutagenesis kit (catalog #210519) obtained from Agilent Technologies is used to 
make specific point mutations leading to a switch in the amino acids. The human wild-type P2X7 
coding sequence (GenBank accession number Y09561.1) introduced in pCDNA 3.1
+
 vector, kindly 
donated by Elena Adinolfi, University of Ferrara, Italy (Elana Adinolfi et al., 2010), was amplified 
in XL10-Gold ultracompetent cells and used for site-directed mutagenesis.  
Primer Design: Two synthetic oligonucleotide primers containing the desired point mutations for 
each SNP were designed as showed in table 1.  
Table 1: Mutagenesis Primers 
489C>T (H155Y) 
Forward 5’-3’ end 
Reverse 5’-3’ end 
 
CCGGAAGGTGTGTAGTGTATGAAGGGAACCAGAAGACC 
GGTCTTCTGGTTCCCTTCATACACTACACACCTTCCGG 
 
946G>A (R307Q) 
Forward 5’-3’ end 
Reverse 5’-3’ end 
 
CAATGTTGAGAAACAGACTCTGATAAAAGTCTTCGGGATCCG 
CGGATCCCGAAGACTTTTATCAGAGTCTGTTTCTCAACATTG 
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1068G>A (A348T) 
Forward 5’-3’ end 
Reverse 5’-3’ end 
 
 
CGGTCTGGCCACTGTGTTCATCGA 
TCGATGAACACAGTGGCCAGACCG 
1405A>G (Q460R) 
Forward 5’-3’ end 
Reverse 5’-3’ end 
 
CCAGAGGAGATACGGCTGCTTAGAAAGGAGGCG 
CGCCTCCTTTCTAAGCAGCCGTATCTCCTCTGG 
 
1513A>C (E496A) 
Forward 5’-3’ end 
Reverse 5’-3’ end 
 
 
TGCCTGGAGGCGCTGTGCTGC 
GCAGCACAGCGCCTCCAGGCA 
Table 1: The single base mutation is underlined and marked in bold. 
Mutagenesis reaction: 
Preparation of sample reaction included: 5 µl of reaction buffer, 2 µl of 40 ng dsDNA template, 
1.25 µl (125 ng) of oligonucleotide primer #1 and 2 (100 ng/ µl), 1 µl of dNTP mix and 1 µl of 
enzyme. 
Thermocycling: 
Cycling parameters 
Segment Cycles Temperature Time 
1 1 95 °C 2 minutes 
2 18 95 °C  20 seconds 
60 °C 10 seconds 
68 °C 30 seconds/kb of 
plasmid length 
3 1 68 °C 5 minutes 
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Dpn I digestion: 
2 µl of Dpn I digestion restrictions enzymes is added directly to each amplification reaction. 
Each reaction mixture was mixed gently and thoroughly. Briefly spin down the reaction mixtures 
and then immediately incubate at 37°C for 5 minutes to digest the parental (i.e., the nonmutated) 
supercoiled dsDNA. 
Transformation of XL10-Gold Ultracompetent cells: 
The XL10-Gold ultracompetent cells are used for transformation by mixing 2 µl of β-ME to 45 µl 
of ultracompetent cells together with 2 µl of the Dpn I-treated DNA from each sample reaction. 
After incubation for 30 min the reaction samples were heat-pulsed in 42°C water bath for 30 
seconds. 2 min of incubation followed by adding 0.5 ml NZY+ broth and incubated the tubes at 
37°C for 1 hour with shaking at 225–250 rpm. After incubation, 150 µl and 250 µl of the reaction 
samples were added on agar plates with Amp
+
 and the transformation plates were incubated at 37°C 
for >16 hours.  
Next day colonies were picked to grow in 250 ml LB
amp+
 media overnight for each of the 
transformed E. coli cells (16-21 hours).  
The following day Qiagens maxi-prep system was applied to isolate high quantity of plasmid DNA 
for eukaryotic transfection. 
Plasmid Maxi-prep System 
The overnight culture E. coli cells was centrifuged at 6000 x g at 4°C for 15 min and pellet was 
resuspended with buffer P1 containing RNAse. Buffer P2 is applied and incubated, followed by 
buffer P3. The lysate was poured into QIA-filters and incubated. The cell lysate was filtered into a 
pre equilibrated QIAGEN-tip.  
Buffer QC was used to wash the tips and buffer QF is applied to elute DNA. Isopropanol is used to 
precipitate DNA followed by centrifugation and removal of supernatant. The DNA pellet is washed 
with 70% ethanol and centrifuged. The pellet was air-dried and resuspended in either H2O or TE 
buffer and kept at -20 °C.   
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All clones were checked by Eurofins MWG Operon to verify every single mutation. Additionally 
two other primers (Forward primer – AAACAGAAGGCCAAGAGCAGCG; Reverse primer - 
AAGTCCATCGCAGGTCTTGG) were used to confirm the whole insert sequence and exclude unwanted 
additional sequence variations.  
 
Transfection of ROS cells with green fluorescent protein 
 
The purpose of this step was to introduce the reporter gene like green fluorescent protein (GFP) to 
observe whether ROS cells are inducible for introduction of foreign DNA and also observe the 
efficiency of the transfection. pmaxGFP vector was kindly provided by Louise Torp Dalgaard. 
Lipofectamine 2000 (Invitrogen) was used to transfect the ROS cells and varies concentration of 
plasmid and lipofectamine was used to find the optimal concentration for transfection of ROS cells. 
Plasmid concentration was in the range of 0.8, 1.0, 1.2, 1.4, 1.6, 1.8 µg and lipofectamine 
concentration in range 1, 2, 3, 4 µl. Control samples were included.  
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Expression of P2X7R in transient transfected cells 
 
In order to determine P2XR expression in transient transfected ROS cells; RT-PCR and western 
blot was conducted. 
RT-PCR 
 
Procedure: 
Transfection 
About 1.0x 10
6
 cells were plated in 5 x 10 cm dishes the day before transfection in order to obtain 
approximately 80 % confluent (wild-type, H155Y, R307Q and A348T).  
The cells were transfected with 24 µg plasmid DNA and 60 µl lipofectamine 2000 as recommended 
by the manufacturer (Invitrogen). Plasmid DNA was diluted in 1.5 ml MEM medium without 
penicillin/serum (w/o P/S) and 60 µl lipofectamine was diluted in 1.5 ml MEM medium w/o P/S.  
The diluted DNA was combined with diluted lipofectamine (total volume of 3 ml) and incubated for 
20 minutes at room temperature. 3 ml of the incubated reaction was added to 10 cm dishes and 
incubated at 37 °C in a CO2 incubator for 48 hours.  
RNA isolation and RT-PCR 
Total RNA was isolated from the transfected cells according to RNeasy mini protocol, using 
RNeasy minikit (Qiagen). Medium was aspirated from the transfected cells and lysed directly in the 
dishes by buffer RLT containing β-mercaptoethanol (β-me). The cell lysates were collected in a 
QIAshredder spin column sitting in a 2 ml collection tube. 70 % ethanol were added to the 
homogenized lysates and mixed well. The samples were transferred to RNeasy spin column placed 
in a 2 ml collection tube and centrifuged for 15 sec at >10000 rpm. Spin column membrane is 
washed with buffer RW1 followed by centrifugation as before. DNAse I with buffer RDD was 
applied to column membrane to remove DNA followed by washing step with buffer RW1 and 
buffer RPE respectively and centrifugation. The RNeasy spin column was placed in a new 
collection tube and RNase free water was applied to the column and centrifuged for 1 min at 
>10000 rpm to elute RNA.  
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RNA content was measured by using spectrophotometer Nanodrop and the purity of the samples 
was close to 2 at the 260/280 absorbance. The RNA was kept at -80 °C until use. 
Total RNA from the transfected ROS cells were used to synthesize cDNA using High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) and amplified by PCR using specific P2X7 
primers.  
Preparation of RT master mix (per 20 µl reaction) included: 2 µl RT buffer, 0.8 µl dNTP, 2 µl RT 
random primers, 1 µl Multiscribe reverse transcriptase, 1 µl RNase Inhibitor, 3.2 µl H2O.  
The 10 µl of RT master mix was mixed with 10 µl of total RNA (5 µg) and centrifuged briefly. The 
mixed reaction was ready for performing reverse transcription in a thermal cycler. The program for 
thermal cycler is following: 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time 10 min 120 min 5 min ∞ 
 
Concentration and purity of cDNA was determined as previously described and kept at -20 °C. 
Polymerase chain reaction 
For identification of P2X7 cDNA, PCR amplification was conducted by using specific rat primers 
recognizing P2X7R gene.  
The PCR reaction included: 2.5 µl 10x PCR buffer, 0.25 µl dNTP (25 mM), 0.75 µl forward primer, 
0.75 µl reverse primer, 0.5 µl HotStar Tag, 5 µl cDNA and H2O up to 25 µl. PCR reaction was 
performed in thermal cycler with following program: 15 min 95°C, 35 cycles: 30sec 94°C; 30sec 
55°C; 60sec 72°C; final extension: 10 min 72°C. 
The PCR products were separated by agarose gel electrophoresis. Gels consisted of 1% agarose 
dissolved in 1xTBE buffer and 3 µl ethidium bromid. 25 µl of samples were mixed with 8 µl 
loading buffer and loaded on the gels along with 1 kb DNA ladder. The gels were visualized by 
using LAS 4000.  
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Western blot 
 
Procedure: 
Transfection 
About 1.0x 10
6
 cells were plated in 5 x 10 cm dishes the day before transfection in order to obtain 
approximately 80 % confluency (wild-type, H155Y, R307Q, A348T).  
The cells were transfected with 24 µg plasmid DNA and 60 µl lipofectamine 2000 as recommended 
by the manufacturer (Invitrogen). Plasmid DNA was diluted in 1.5 ml MEM medium without 
penicillin/serum (w/o P/S) and 60 µl lipofectamine was diluted in 1.5 ml MEM medium w/o P/S.  
The diluted DNA was combined with diluted lipofectamine (total volume of 3 ml) and incubated for 
20 minutes at room temperature. 3 ml of the incubated reaction was added to 10 cm dishes and 
incubated at 37 °C in a CO2 incubator for 48 hours.  
Determination of protein concentration 
In order to determine protein concentration the transfected cell culture (same procedure as  )  was 
subjected to lysis buffer with proteases- and phosphatses inhibitors and incubated on ice for 15 
minutes. The cells were collected in an eppendorf tube and centrifuged at 13,000 rpm/4 °C for 10 
min and supernatant transferred to a new eppendorf tube. A standard series of solutions of known 
protein concentration using bovine serum albumin (BSA), commonly used as a protein standard, 
was prepared. The standard row was used to determine the protein concentration with BIO-RAD 
kit. The sample was then subjected to SDS-PAGE electrophoresis using a 4-20 % Runblue SDS gel 
(Expedeon) and transferred to a PVDF membrane (GE healthcare). The membrane was blocked by 
2% blocking buffer and then incubated overnight with primary rabbit antibody (Sigma-Aldrich) 
against P2X7 purinergic receptor (1:200 dilutions). Next day membrane was incubated for 1 hour 
with secondary goat-anti-rabbit-HRP (horseradish peroxidase) antibody (1:40.000) and protein 
visualization was done by using LAS-4000. 
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Real time qPCR 
 
Procedure: 
Transfection 
ROS cells were plated at a density of 2.0 x 10
6
 and 1.0 x 10
6
 in a 6 cm culture dishes in culture 
medium. Next day cells were observed to be either 100 % confluent or 80 % confluent. Total RNA 
was isolated from the 100 % confluent cells for background controls using RNeasy minikit (Qiagen) 
according to manufacturer’s guidelines and kept in -80 °C freezer for later use. Concentration and 
purity of RNA was determined by spectrophotometer NanoDrop.  
The 80 % confluent cells were used for transfection with pCDNA3.1
+
 containing P2X7 gen. The 
manufacturer recommendation of 8 µg plasmid and 20 µl lipofectamine for a 6 cm culture dish is 
followed. The DNA (8 µg) was diluted in 0.5 ml MEM medium w/o P/S and 20 µl lipofectamine 
was diluted in 0.5 ml MEM medium w/o P/S. The diluted DNA was combined with diluted 
lipofectamine (total volume of 1 ml) and incubated for 20 minutes at room temperature. 1 ml of the 
incubated reaction was added to 6 cm dishes and incubated at 37 °C in a CO2 incubator for 48 
hours.   
1 hour before total RNA isolation cells were stimulated with 100 µM 3'-O-(4-benzoyl) benzoyl 
ATP (BzATP). Total RNA from the transfected cells were isolated using RNeasy minikit. 
Concentration and purity was determined by NanoDrop and kept in -80 °C freezer.  
The transfected cells include 3 different single nucleotide polymorphism (SNPs); 489C>T (H155Y) 
variant, 946G>A (R307Q) variant, 1068G>A (A348T) variant respectively, empty plasmid 
(pCDNA3.1
+
 without P2X7 gen) and wild-type.  
 
cDNA Reverse Transcription 
Total RNA from the transfected cells and non-transfected cells were used to synthesize cDNA using 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).  
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Preparation of RT master mix (per 20 µl reaction) included: 2 µl RT buffer, 0.8 µl dNTP, 2 µl RT 
random primers, 1 µl Multiscribe reverse transcriptase, 1 µl RNase Inhibitor, 3.2 µl H2O.  
The 10 µl of RT master mix was mixed with 10 µl of total RNA (5 µg) and centrifuged briefly. The 
mixed reaction was ready for performing reverse transcription in a thermal cycler. The program for 
thermal cycler is following: 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time 10 min 120 min 5 min ∞ 
 
The ΔΔCT method (relative quantification) was used to quantify the gene expression of various 
bone markers (Runx-2, Sp7, Alkaline phosphatase, Bglap, Ibsp, collagen-1, Ptgs-2, P2X7) for 
treated/transfected wild-type, 3 different SNPs and untreated/not transfected sample. A standard 
curve was made to ensure efficiency of assay and to determine relevant cDNA dilution. 
All samples were normalized with endogenous control gene (GAPDH) and each sample reaction 
was performed in triplicate. 
 
Calcium Assay 
Preparation of reagents/buffer 
Washing buffer was prepared by dissolving 0,035 g Probenecid (285.4 g/mol) in 250 µl NaOH 
(0,6N) followed by adding 50 ml HBSS++HEPES buffer. pH adjusted to 7,35 with 0,6 NaOH. 
Loading buffer was prepared by dissolving 50 µg of fura-2/AM (stock solution, 2mM) in 23 µl 
DMSO and distributed in 3 µl aliquots. One aliquote Fura-2 was mixed by vortexing with equal 
amounts of Pluronic F-127. Then 1.5 ml washing buffer was added and vortex again (stored in the 
dark until use). 
Preparation of agonists: 
BzATP (100 mM): 25 mg dissolved in 349 µl sterile H2O. 
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ATP (100 mM): 15 mg dissolved in 250 µl sterile H20. 
BzATP and ATP are further diluted in NOVOSTAR to the desired concentration. The cells are 
subjected to a final concentration of 1mM BzATP and 10 mM ATP and 1 mM ATP. 
Procedure 
Transfection 
ROS cells were plated at a density of 1.0x10
4
 in each well of a 96-well plate. After 2 days ROS 
cells were approximately 80-90 % confluent and ready for transfection. The cells were transfected 
with 0.2 µg plasmid DNA and 0.5 µl lipofectamine 2000.  
Plasmid DNA was diluted in 25 µl MEM medium w/o P/S and 0.5 µl lipofectamine was diluted in a 
25 µl MEM medium w/o P/S. The diluted DNA was combined with diluted lipofectamine (total 
volume of 50 µl) and incubated for 20 minutes at room temperature. 50 µl of incubated reaction was 
added to each well in 96-well plate and incubated at 37 °C in a CO2 incubator for 48 hours.  
Loading of the cells  
Culture medium was aspirated from the wells. 50 µl loading buffer was gently added in the wells. 
The 96-well plate was wrapped in aluminum foil and incubated for 1 hour in the CO2 incubator at 
37 °C. Loading buffer was aspirated and cells was washed gently with 100 µl washing buffer and 
discarded. 90 µl washing buffer was added to the wells and incubated for 30 minutes in CO2 
incubator.  
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Calcium imaging  
Before measuring the 96-well plate, reagents with washing buffer, agonists (bzATP, ATP) have to 
be placed in NOVOSTAR and priming step is necessary to ensure that any clot or residual are 
removed before measuring the plate. The programmed Ca
2+
 test is selected and measurement starts.  
Plate setup: 96-well plate 
  1 2 3 4 5 6 7 8 9 10 11 12 
A Blank                       
B Blank 
No transfection 
vehicle 
No transfection  
BzATP 
Empty 
vehicle 
Empty 
BzATP 
Wt 
vehicle 
Wt 
BzATP 
Wt 
BzATP 
155 
vehicle 
155 
BzATP 
155 
BzATP   
C Blank 
No tranfection 
Vehicle 
No transfection  
BzATP 
Empty 
vehicle 
Empty 
BzATP 
Wt 
vehicle 
Wt 
BzATP 
Wt 
BzATP 
155 
vehicle 
155 
BzATP 
155 
BzATP   
D Blank               
307 
vehicle 
307 
BzATP 
307 
BzATP   
E                 
307 
vehicle 
307 
BzATP 
307 
BzATP   
F                 
348 
vehicle 
348 
BzATP 
348 
BzATP   
G 
 
ATP 10 mM ATP 10 mM 
ATP 
1mM 
ATP 
1mM        
348 
vehicle 
348 
BzATP 
348 
BzATP   
H                         
Table 2: Positive control: ATP, Vehicle: washing buffer. Wt: wild-type. 
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Statistical Analysis 
 
Statistical significance of data was evaluated using student’s t-test and probability values below 
0.05 (P<0.05) were considered significant by comparing differences between the SNPs and wild-
type. Data are shown as means ±SEM. 
Results 
Site directed mutagenesis 
Table below shows the desired point mutations leading to a switch in the amino acids. 
489C>T 
(H155Y) 
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946G>A 
(R307Q) 
 
 
1068G>A 
(A348T) 
 
 
 
1405A>G 
(Q460R) 
 
 
 
 
Unable to create the specific mutation with different primers 
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1513A>C 
(E496A) 
 
 
 
We were able to produce this specific mutation but after a transformation step to 
produce more plasmid the mutation unfortunatly disappeared.  
 
Table 3: Bioedit program was used for alignment of the obtained sequence with wild-type hP2X7 
coding sequence (GenBank accession number Y09561.1). Chromas lite2.0 was used to open 
chromatogram files from MWG operon and also used for analysis of the obtained chromatograms. 
 
The desired mutations were obtained by using a commercial kit though several attempts were made 
to obtain the mutations by a protocol at Roskilde University. In several cases uncertainty in the 
analyzed sequence from MWG operon resulted in rejection of the sequence and necessitates 
repeating the process of making desired mutations. With more experience gained throughout the 
mutagenesis process it became clear that many of the unwanted mutations in the chromatogram of 
nucleotides were due to some uncertainty in the sequencing method. 
In the end we succeeded to obtain 3 of the 5 desired mutations. The G496A mutation was produced, 
unfortunately during a transformation step the mutation was changed back to wild-type nucleotide 
and due to lack of time we decided not to redo the mutagenesis reaction. Attempts of gaining the 
Q460R mutation were unsuccessful.    
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Transfection of ROS cells with GFP 
24 hour post-transfection 
Due the amount of pictures taken, not all examples will be showed. The showed examples will 
provide an overall understanding of the transfection efficiency. 1.0 µg plasmid, 1.8 µg plasmid and 
2 µl lipofectamine are not shown. 
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48 hours post-transfection 
1.0 µg plasmid, 1.8 µg plasmid and 2 µl lipofectamine is omitted from the table below: 
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The expression of GFP 48-hour post-transfection is was distinct from 24-hour post-transfection.  An 
overall transfection ratio of ROS cells after 24-hours of transfection lies somewhere between 15-
20% while approximately 30-35% of the cells are transfected after 48-hours of transfection. This 
evidently shows and confirm that the cells uptake and express GFP plasmid mostly 48-hour post-
transfection. After 72-hour post-transfection GFP expression is almost at the same level as 48 hour 
post-transfection (results not shown).  
  
Expression of P2X7R in transient transfected cells 
RT-PCR and Western Blot  
 
Investigation of the expression of transfected ROS cells with P2X7R in RT-PCR revealed that 
P2X7 mRNA was not expressed when using specific primers against P2X7R. 
 
 
 
 
 
 
 
 
Throughout the experiments with human P2X7 PCR several parameters was varied to optimize the 
reactions without succeeding. The parameters that were altered included reagent concentrations, 
cycling temperatures and cycle number.   
Figure 10: RT-PCR was performed on RNA extracted from transient transfected cells. No positive results 
were obtained for the transient transfected ROS cells. The only positive result of P2X7 was on two RNA 
extractions from rat spleen (positive control – lane 1 and 2) and not from ROS cells (negative – lane 3 and 4) 
at 53 °C followed by the same setup at 55 °C. 5 µg of cDNA was used. 
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6 
Total protein was isolated from the SaOS2 cells and used as positive controls. The expression of 
P2X7R in SaOS2 cells has been confirmed by several studies (Gartland et al., 2001; Alqallaf et al., 
2009) and frequently used as positive control for detection of P2X7R in different assays. Using the 
rat P2X7R antibody bands were seen in the positive control at ~ 65 kDa but also to small bands at ~ 
70 kDa (figure 11A, lane 1 and 2). The expected molecular weight of P2X7R is approximately 69 
kDA (Suprenant et al., 1996), although there are variations in the expected sizes of the bands for 
P2X7R probably due to glycosylation of the receptor. Bands at ~ 65 kDa were seen for wild-type, 
three SNPs, and a small band was seen for non-transfected ROS cells at ~ 65 kDa. We also 
observed bands at ~70 kDa for 155 SNP, 307SNP, 348 SNP although the bands are not sharp due to 
low quality of the picture. Generally a lot of bands were detected as indicted by figure 11A, and 
therefore we conducted optimization of our protocol for removing some of the unspecific 
background without succeeding to remove the unspecific binding. Figure 15B shows the experiment 
without primary antibody and as indicated we see bands at ~ 65 kDa for wildtype, 348 SNP, non-
transfected ROS cells and empty plasmid. We detected a weak band for positive control at ~ 65 kDa 
and 70 kDa. 
  
Figure 11: Representative example of western blotting for transient transfected P2X7R in ROS cells. A) Positive 
control (SaOS2 cells, lane 1 and 2), Wt (lane 3), 155 SNP (lane 4), 307 SNP (lane 5), 348 (lane 6), empty plasmid (lane 
7), non-transfected ROS cells (lane 8). 25 µg was used for all samples. B) Without primary antibody; Wt (lane 1), 348 
SNP (lane 2), Non-transfected ROS cells (lane 3), empty plasmid (lane 4), Positive control (SaOS2 cells, lane 5). n=5. 
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Real-time -qPCR 
 
We used q-PCR to determine whether the different SNPs of P2X7 receptors have any effect on the 
expression of  transcriptionsfactors, extracellularmatrix (ECM)  proteins both collagen and 
noncolleganoues proteins, which are  important for differentiation and the mineralization of the 
bone suface. 
 
 
There was no significant difference in expression of Runx-2 when wildtype is compared with 3 
SNPs and no significant difference between wild-type and empty plasmid (figure 12A). However 
when comparing expression of Sp7 wild-type with 3 SNPs there was an significant increase in 
expression of Sp7 in H155Y SNP and A348T SNP.  However no significant difference was 
observed between wild-type and empty plasmid (figure 12B). 
 
 
Figure 12:  Expression of early differentiation transcriptions factors Runx-2 and Sp7 by Real-time qPCR, which 
are essential for osteoblast differentiation. Comparison of Runx-2 and Sp7 expression of three SNPs and empty 
plasmid with wild-type (Students t-test). *Indicates significant difference from wild-type (p<0.05). Data are 
expressed as means ± SEM. n=5. Empty, empty plasmid; Wt, wild-type. 
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IBSP and BGLAP are some of the major structural non-collagenous protein in the bone matrix. 
Increases in expression of these proteins are indicative of bone formation particularly BGLAP is 
often used as a bone marker because it is solely secreted by osteoblasts.  
There was no significant increase in expression of IBSP when comparing H155Y and R307Q SNPs 
with wild-type though there was a significant increase in R307Q SNP compared to wild-type. 
However, no difference was found between wild-type and empty plasmid in relation to IBSP 
expression.     
Significant increases were measured in the expression of BGLAP in 3 SNPs compared to wild-type. 
There was also a significant increase in expression of BGLAP in empty plasmid when compared to 
wild-type.   
  
Figure 13:  Expression of non-collagenous proteins of ECM by Real-time qPCR. Comparison of IBSP and BGLAP 
expression of 3 SNPs and empty plasmid with wild-type (Students t-test). *Indicates significant from wild-type 
(p<0.05). Data are expressed as means ± SEM. n=5. 
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The primary functional activity of the active/mature osteoblasts is production of an extracellular 
matrix with ability to mineralize the ECM. Alkaline phosphatase is considered as a hallmark of the 
osteoblast phenotype and widely accepted marker of new bone formation, due to fact that high 
levels of alkaline phosphatase is detected in active osteoblasts.  
There was significant increase in the alkaline phosphate expression when comparing the 3 SNPs 
with wild-type. Empty plasmid expression of alkaline phosphatase was also significantly increased 
compared to wild-type (figure 14A).  
Ptgs2 (COX2) is an enzyme involved in the conversion of arachidonic acid to prostaglandins. In a 
recent study (Grol et al., 2013) they demonstrated that transcription factor nuclear factor of 
activated T-cells (NFAT) caused a robust expression of the NFAT target gene Ptgs2 solely when 
high level of ATP is applied to P2 receptors. Activation of NFAT requires an increase in the 
cytosolic Ca
2+
 level and downstream effect of calcium increase in the cytosol results in activation of 
NFAT. 
Ptgs2 expression in H155Y SNP was significantly decreased compared to wild-type, while no 
difference was observed between R307Q and A348T SNP. However there was significant decrease 
in the expression of Ptgs2 in empty plasmid compared to wild-type. 
Figure 14: Expression of ALPL and Ptgs2. Comparison of ALPL and Ptgs2 expression of the three SNPs with wild-
type (Students t-test). *Indicates significant difference from wild-type (p<0.05). Data are expressed as means ± 
SEM. n=5 
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Collagen type-1 is the major matrix component synthesized by osteoblasts, which comprises nearly 
90% of the bone ECM and provides the essential substrate for mineral deposition, hence important 
to investigate the expression of collagen in order to elucidate the effect of P2X7R SNPs in 
osteoblasts.  
The expression of collagen showed that there was no significant difference between the 3 SNPs 
compared to wild-type. The same was applicable for wild-type and empty plasmid. 
Since RT-PCR failed to show expression of human P2X7 in transient transfected ROS cells, we 
included P2X7 in RT-qPCR to demonstrate the expression of P2X7 mRNA in transfected ROS 
cells. The results demonstrate that P2X7 was expressed on the mRNA level. There was a significant 
increase in expression of wild-type, the three SNPs compared to empty plasmid. Discrepancy in 
some of the qPCR measurements resulted in a very high SEM for H155Y SNPs.  
  
Figure 15:  Expression of Col-1 and P2X7. A) Comparison of Col-1 expression of the three SNPs with wild-type 
(Students t-test). B) Comparison of P2X7 expression of the 3 SNPs and wild-type with empty plasmid. *Indicates 
significant difference (p<0.05). Data are expressed as means ± SEM. n=5. 
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Intracellular calcium 
 
In order to investigate the functional significance of P2X7R we assessed Ca
2+
 signaling elicited by 
BzATP and ATP. ROS transfected cells were loaded with calcium sensitive dye fura-2 and changes 
in [Ca
2+
]i were monitored by NOVOSTAR plate reader. High BzATP concentrations (10 mM) were 
applied to the cells to activate the P2X7 receptors.  
 
 
 
There was a significant increase in intracellular calcium in wild-type compared to empty plasmid, 
which indicates that there are P2 receptors probably P2X7R. In the case of H155Y SNP the overall 
values was higher than wild-type response although not significant. Interestingly, R307Q SNP 
response was significantly decreased compared to wild-type while A348T SNP response was 
significantly higher than wild-type. 
 
  
Figure 16: Functional analysis of P2X7R mediated [Ca2+]I change. Emp, Empty plasmid; Wt, wild-type; 
V, vehicle; Bz, BzATP. *Indicates significant difference from wild-type (p<0.05). Data are expressed 
as means ± SEM. n=8 
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Discussion 
ROS 17/2.8 osteoblast-like cell as a model for osteoblasts 
 
ROS 17/2.8 cells were derived from rat osteosarcoma cells and acquired the capacity for infinite 
growth and division. There are many advantages of using immortalized cell line as ROS 17/2.8 
including easy to maintain the cell culture, an unlimited amount of cells due to immortalization and 
a relatively phenotypic stability. However evidence exists for phenotypic heterogeneity among this 
cell line which is correlated to prolonged passaging of cells (Grigoriadis et al., 1985) which in these 
experiments was avoided by replacing the cells above 15-20 passages. Additionally these cells do 
not reflect the whole range of phenotypic features of primary osteoblast cells.  
However ROS 17/2.8 cells display characteristic features of osteoblastic cells including high levels 
of alkaline phosphatase, expression of osteocalcin mRNA, production of calcified matrix. 
Furthermore they respond to TGFβ with increase in alkaline phosphatase, collagen type I, 
osteonectin, osteopontin and osteocalcin mRNA (Majeska et al., 1982; Price et al., 1980; Shteyer 
1986; Noda et al., 1987&1988). Beside the osteoblastic features the selection of ROS 17/2.8 was 
crucial for conducting the planned experiments since ROS 17/2.8 cell line is probably the only cell 
line without P2X7 receptors. To my best knowledge, only Jørgensen et al. investigated the 
expression of P2X7R in ROS 17/2.8 cell line and with reservation no reports have shown 
expression of P2X7R in this cell line. Furthermore characterization of P2X7R in ROS cells was 
conducted in the beginning of this master thesis without being able to show rat P2X7 mRNA 
though those experiments were associated with some uncertainty due to experimental procedures. 
Optimization of the protocol resulted in expression of P2X7 mRNA in positive controls from rat but 
not in ROS cells.  
 
Are P2 receptors expressed in transient transfected ROS cells? 
 
RT-PCR analysis of total RNA from transient transfected ROS cells did not confirmed the 
expression of P2X7 mRNA. Currently only one preliminary study have investigated the role of 
transfected P2X7R SNPs to determine the effects on osteoblastic cells (Gartland et al., 2013). 
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Interestingly they were not able to detect expression of P2X7R unless it was co-transfected with a 
naturally occurring isoform of P2X7, splice variant B (P2X7B), indicating that P2X7 complex 
interacts with other splice variants to form a functional receptor. Other studies have indicated that 
P2X7 can establish heteromeric complexes with P2X4 subunits however heteromeric receptors of 
P2X4 and P2X7 shows a decreased agonist activation compared to homomeric receptors (Dubyak et 
al., 2007; Guo et al., 2007).  
The absence of expression can also be due to low transfection efficiency. The pCDNA 3.1
+
 vector 
used in this report lacks a reporter gene like GFP therefore we were unable to measure the 
transfection efficiency. Escher et al. (2005) investigated the transfection efficiency of various 
transfection methods including lipofectamine 2000, to estimate expression levels in murine 
macrophage RAW 264.7 cells. Transfection efficiency of the most methods resulted in 5-10 % 
expression level including lipofectamine 2000; DEAE dextran method was marginally better than 
the other methods. They investigated whether methylation in CpG-rich islands in the CMV-
promoter contributed to the low transfection efficiency.  They observed that demethylation of the 
CMC promoter resulted in 80-100% transfection efficiency in DEAE dextran methods thus 
providing evidence for methylation in transient transfected cells play a role in expression of 
macrophage RAW 264.7 cells. It is impossible to predict whether the same occurs in the transient 
transfected ROS cells because of the lack of reporter gene in this particular plasmid. Application of 
this method should be done with consideration since methylation eradication can also affect other 
genes in the cells. Other authors have investigated the transfection efficiency of lipofectamine 2000 
in HeLa and NT2/D1 cells where different parameters was varied to evaluate the highest 
transfection efficiency. The highest transfection efficiency for HeLa cells averaging 20% when they 
used 2.5 µg plasmid DNA, which was above the manufacturers’ recommended range for a 35 mm 
dishes. With NT2/D1 cells a transfection efficiency of 28 % was obtained with 1.5 µg plasmid 
DNA 24 hour post-transfection, which was within the range of manufacturers’ guidelines (Gordana 
et al., 2003). These results are similar to that with pmax GFP transfection conducted by us where 
transfection efficiency between 15-20 % was obtained after 24 hours of transfection. Another study 
showed a transfection efficiency of approximately 30% in HeLa cells with 1 µg of plasmid DNA 
and 4 µl of lipofectamine after 24 hours of transfection (Asgharian et al., 2014). 
Furthermore low transfection efficiency can be caused by low competency of transferring DNA into 
cells, which may be the case in our experiments.  
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Human P2X7R mRNA was not detected by western blot in transient transfected ROS cells. 
Although bands were detected at 65 kDa for positive control, wild-type and the three SNPs we also 
detected bands at 70 kDa for positive controls and some of the SNPs (figure 11A). These bands are 
weak but detection of them cannot be ignored by the fact that a lot of bands are detected which 
indicates unspecific binding. The observations from others have been that even though the predicted 
molecular weight of P2X7R is ~69 kDa, reports of 85 kDa P2X7R exists (Wang et al., 2005). They 
observed that the high levels of BzATP induced Ca
2+
 influx and influx of ethidium bromide was 
greater in cells cultured for 6 days than cells cultured for 2 days. The number of culture days also 
affected the levels of P2X7R forms since the predominant form were 65 kDa in 2 day cultures while 
levels of 85 kDa in 6 day cultures were greater than 2 day cultures, suggesting that the mature and 
functional form (glycosylated form) of P2X7R is 85 kDa. Other authors have found that the native 
and functional P2X7R are ~65-69 kDa and deglycosylation of P2X7R receptor resulted in reduction 
of P2X7R by 8 kDa suggesting that the functional P2X7R are between 65-69 kDa (Alqallaf et al., 
2009, Lee et al., 2006).  
Although we assume that the obtained results in figure 11A are indicative of the native and 
functional receptor at ~65 kDa, the results in figure 11B where the primary antibody was removed 
shows band at ~65 kDa, refute the assumption that it was the functional P2X7R making it difficult 
to rely on the results. The secondary antibody binds unspecifically to many proteins and thus must 
be diluted further or replaced to get positive results.  
Before we find out that secondary antibody probably caused the background staining we modified 
our protocol to decrease the background staining which included the dilution of primary antibody, 
different concentrations of protein homogenate, longer washing steps and dilution of secondary 
antibody. In order to get positive and reliable results full optimization of the western blot protocol is 
required and due to time shortage we were not able to try to change secondary antibody or maybe 
apply an another protocol. 
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Influence of P2X7R SNPs on Gene Expression  
 
This is the first report investigating the role of P2X7R SNPs in gene expression of osteoblast-
related transcription factors and specific bone markers.  
Osteoblast differentiation is multistep process where modulations are exerted by regulatory factors 
in a highly regulated manner to support differentiation and proliferation and subsequently the 
expression of genes associated with the organization and mineralization of the extracellular matrix. 
In that context the lineage of the mature osteoblasts constitute highly differentiated cells which 
differ in their properties at different stages of development, thus providing a distinctive phenotype, 
morphology and biosynthetic pattern to determine the sequential differentiation stage. Two of the 
most crucial transcription factors for osteoblast differentiation, Runx2 and Sp7, showed different 
expression pattern in ROS transfected cells. The Runx2 expression did not show significant 
difference between any of the selected parameters confirming in some extent that ROS cells are 
matured osteoblast and expression levels are equal. Interestingly Sp7 expression was significantly 
increased in H155Y SNP and 307 SNP, since Sp7 works downstream of Runx2 these results are 
unexpected. Conversely P2X7R are not expressed in ROS cells, therefore expression of P2X7R is 
not necessary for the osteoblastic properties of these cells. 
IBSP is a major non-collagenous structural protein of bone extracellular matrix, secreted by both 
osteoclasts and osteoblasts and binds strongly to hydroxyapatite via its negatively charged domains. 
IBSP also contain a Arg-Gly-Asp (RGD) cell attachment sequence which is important for the cell-
binding properties of fibronectin and vitronectin (Watts, 1999; Ogata, 2008). Our results showed a 
significant higher expression of A348T SNP compared to wild-type. Chen et al. (1992) showed that 
IBSP rat mRNA expression was restricted to the cells which was actively forming the mineralizing 
tissues of bone, thus indicating that IBSP is first expressed on the onset of bone formation. Other 
finds that IBSP promotes adhesion of osteoclast to bone surface and also inhibits the differentiation 
of new osteoclasts (Raynal et al., 1996). The A348T SNP is a GOF polymorphism; increasing of the 
IBSP mRNA upon transfection may indicate a role in bone mineralization although this finding has 
to be investigated further.  
 BGLAP is the most abundant non-collagenous structural protein of the bone matrix and expressed 
only by osteoblasts.  
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It is a vitamin K dependent protein which is important for the ɣ carboxylation of its three glutamic 
acid residues. These glutamic acid residues promote BGLAP binding to hydroxyapatite (Marcus et 
al., 2013; Hannon et al., 2006).  
Ducy et al. (1996) interestingly showed that BGLAP deficient mice developed a phenotype marked 
by higher bone mass. Comparison of the obtained results in our experiment where the 3 SNPs have 
significant higher expression of BGLAP than wild-type, do not elucidate the role of P2X7R SNPs 
in expression of BGLAP.  
Bone alkaline phosphatase is a membrane bound osteoblast enzyme and hydrolyses pyrophosphate 
thereby removing an inhibitor of osteogenesis while creating the inorganic phosphate that is 
required for deposition of hydroxyapatite. The role of alkaline phosphatase in bone mineralization 
became evident in the case of hypophosphatasia, an inheritable disorder where deficiency in 
alkaline phosphatase leads to a defective bone formation (Balcerzak et al., 2003). Alkaline 
phosphatase is widely accepted marker of new bone formation, due to fact that high levels of 
alkaline phosphatase is detected in active and mature osteoblasts (Marcus et al., 2013). Alkaline 
phosphatase expression was increased in the 3 SNPs compared to wild-type, which is unexpected. 
Although these results indicate a gain of function for all 3 SNPs it is probably not the case since 
empty-plasmid alkaline phosphatase expression was also significant higher than wild-type 
suggesting an equal alkaline phosphatase expression in all SNPs with the exception of wild-type.  
As mentioned earlier, Ptgs2 (COX2) is an enzyme involved in the conversion of arachidonic acid to 
prostaglandins. The reason why it was interesting to investigate the effect of P2X7R SNPs 
expression on Ptgs2 was based on a recent publication from Grol and colleague’s (2013). They 
demonstrated that transcription factor nuclear factor of activated T-cells (NFAT) caused a robust 
expression of the NFAT target gene Ptgs2 solely when high level of ATP was applied to P2X7 
receptors. High ATP concentrations activate the P2X7R and induce more sustained Ca
2+
-NFAT 
signaling in the cytosol and thereby induce a robust Ptgs2 expression. Ptgs2 and prostaglandins 
plays an important role in osteoblast differentiation and responses to mechanical stimuli (Blackwell 
et al., 2010). Therefore it was relevant to investigate whether P2XR SNPs have any influence on 
expression of Ptgs2. Our results showed no significant differences between wild-type expression of 
Ptgs2 and R307Q and A348T SNPs. Although we observed a significant decrease in expression of 
Ptgs2 in H155Y SNP and that wild-type had the highest expression of Ptgs2. Our results do not 
indicate a role for P2X7R SNPs in Ptgs2 expression.  
59 
 
Type I Collagen is the major matrix component synthesized by osteoblasts and comprises 
approximately 90% of the organic bone matrix, thus providing the essential substrate for mineral 
deposition. Our results did not show any differences between any of the SNPs compared to wild-
type in collagen type I expression. 
The evidence for expression of P2X7 mRNA was shown by Real-time qPCR where the measured 
amount of P2X7 was significantly higher than empty plasmid. These results evidently confirm the 
expression of human P2X7R cDNA in wild-type and the 3 SNPs of ROS transfected cells. There 
was a significant decrease in R307Q SNP expression of P2X7 compared to wild-type, H155Y and 
R307Q SNPs. The plausible explanation for this decrease may be due to a lower concentration of 
plasmid DNA used in the assay rather than a loss of function of the receptor.  
 
Taken together these results do not show an unambiguous role of the P2X7R SNPs in the 
expression of selective bone markers. We need to take in consideration that transfection efficiency 
most likely affected the outcome of these findings and further investigation must be done with a 
reporter gene like GFP to determine the transfection efficiency to elucidate the role of P2X7R SNPs 
in osteoblasts. The obvious step would be to construct stable transfectants to investigate the long 
term expression of bone markers and simultaneously the stable transfectants provides basis for 
measurement of bone mineralization by a mineralization assay. These steps will provide much 
stronger evidence for implication of P2X7R SNPs in osteoblasts. 
 
Functional Analysis of P2X7R in transfected ROS cells  
 
The functional analysis of P2X7R SNPs by measuring the increase in intracellular calcium upon 
activation of P2X7R showed both GOF and LOF properties for two of the SNPs, A348T and 
R307Q, respectively. These results are an extension of findings in several cohort studies where 
genetic polymorphisms in terms of both LOF and GOF have been associated with decreased or 
increased BMD and fracture incidence, respectively (Jørgensen et al., 2012; Gartland et al., 2012).  
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Several studies have been conducted to investigate the effects of P2X7 SNPs in terms of their 
effects on the ion channel function by measuring the agonist-induced cytosolic calcium levels, ionic 
currents and dye uptake. In this experiment H155Y SNP did not showed a significant increase in the 
cytosolic calcium compared to wild-type, nevertheless there was significant increase in some of the 
plates, indicating a GOF in the P2X7R. Although the H155Y is not highly conserved in the 
mammalians P2X7R family, it exhibit significant changes in the receptor functions. It has been 
shown to increase the cytosolic calcium level and dye uptake in lymphocytes upon agonist 
activation, indicating an enhancement of the receptor function (Cabrini et al., 2005; Portales-
Cervantes et al., 2012). Interestingly reversing the P2X7R mutation from H155Y to Y155H in rat 
resulted in the opposing effects by reducing the amplitude of agonist-induced ionic currents 
(Bradley et al., 2011). Furthermore they investigated whether 6 substitutions of His155 residues 
bearing side chains have any effect on the receptor function and none of the substitution mimicked 
the His155Y mutation indicating that the Tyr is unique to enhance the receptor function. They also 
demonstrated that H155Y increased the surface expression of P2X7R while the reversing mutation 
Y155H reduced the surface expression. For the first time H155Y SNP role in osteoblast-like cells 
have been investigated in relation to determine the receptor function. Although no significant 
increase in cytosolic calcium was measured further analysis of this SNP might reveal it as a GOF 
receptor. 
A348T mutation is located in the TM2 helix and on the intracellular side of the ion channel (Jiang et 
al., 2013). As stated above A348T mutations have been associated with osteoporosis in post-
menopausal women and with anxiety disorders (Jørgensen et al.,2012; Erhardt et al., 2007). 
Functional analysis of the A348T SNP has shown increased ionic currents and dye uptake in several 
studies (Cabrini et al., 2005; Roger et al., 2010; Bradley et al., 2011), indicating that mutational 
effects on the ion channel function are consistent with the structural location of this particular 
mutation. Furthermore our results substantiate the findings that A348T mutation leads to a hyper-
functional receptor upon agonist activation of the P2X7R.  
R307Q is situated in the extracellular loop specifically located in the N-terminus of the β14 strand 
and is highly conserved between the mammalian P2X7R (Jiang et al., 2013). Different cohort 
studies have provided consistent evidence for association of R307Q mutation with reduced BMD, 
increased bone loss and high fracture risk (Gartland et al., 2012; Jørgensen et al., 2012).  
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Functional studies have been conducted to show that R307Q mutation leads to strongly impaired or 
complete loss of agonist-induced dye uptake in monocytes, macrophage and lymphocytes (Gu et al., 
2004). A possible postulate by Jiang et al., may explain the loss of function of  Arg307Gln in 
P2X7R; Arg 307 corresponds to Arg 312 structure of the zebra fish P2X4.1R and Arg 312 interacts 
with highly conserved residues by a network of hydrogen bonding and salt-bridge interactions. The 
same highly conserved residues exists in human P2X7R and mutations in the Arg 312 to glutamine 
or to another positively charged lysine in zebra fish P2X4.1R results in loss of the most of these 
interactions and disruptions of these interactions may be cause of the impaired P2X7R observed in 
our study and other.  
 
The question to be asked is what effect the enhancement or impairment of the P2X7R may exert on 
intracellular pathways in osteoblasts and what evidence exists for activation of cellular pathways. 
P2X7R have been shown to mediate extracellular signal-regulated kinase (ERK) 1/2 activation by 
FSS in MC3T3-E1 pre-osteoblastic cells (Liu et al., 2008). The authors showed that extracellular 
Ca
2+
 entry through the L-type voltage-sensitive Ca2+ channel (L-VSCC) and the mechanosensitive, 
cation-selective channel (MSCC) was essential for the activation of ERK 1/2 through activation of 
P2X7 receptors. Furthermore they showed that FSS-induced ERK1/2 phosphorylation requires 
Ca
2+
-dependent ATP release, however both increased [Ca2+]i and PKC activation are needed for 
complete activation. Increase in cytosolic Ca
2+
 activates the ERK/MAPK signaling pathway; this 
pathway has been implicated in the regulation of cellular growth, differentiation and apoptosis in 
several cell types including osteoblasts. ERK plays an essential role in activation of various 
osteogenic genes such as RUNX2, RANKL, COX2 and c-fos (Okumura et al., 2008; Liu et al., 
2008). Another study also showed phosphorylation of ERK 1/2 upon FSS followed by an increase 
in c-fos, which is involved in cell proliferation, differentiation and survival (Okumura et al., 2008).  
Agonist-induced P2X7R in MC3T3-E1 cells leads to mineral deposition and P2X7R activation 
stimulates osteogenesis by activation of alkaline phosphatase which is thought to play a role in 
mineralization by hydrolyzing inorganic pyrophosphate (PPi) (Nakano et al., 2007; Panupinthu et 
al., 2008). 
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Panupinthu et al., have suggested that P2X7R stimulation leads to increased membrane blebbing 
and increased PLD and PLA2 activity, resulting in production of LPA. LPA may acts on its receptor 
(LPAR) which stimulates Rho-associated kinase and cause membrane blebbing. The same author’s 
suggested in a later study that activation P2X7R leads to production of LPA and PLA2. PLA2 leads 
to production of COX metabolites such as prostaglandins. The downstream effect of prostaglandins 
and LPA is up-regulation of osteoblast markers such as Osterix (SP7) and osteocalcin, which 
stimulates bone mineralization. 
As mentioned above Grol et al., demonstrated that high ATP activation of P2X7R elicited markedly 
expression of the NFAT target gene Ptgs2 (Cox-2), which in turn converts arachidonic acid to 
prostaglandins.  
 
Taken together our results substantiate the existing findings that A348T and R307Q leads to an 
enhancement and impaired P2X7R function, respectively. H155Y did not show a significant 
increase although some observations were increased significantly. These results must be further 
evaluated by conducting more extensive experiments including dye uptake experiments, 
mineralization assay and ionic current measurements. The above mentioned studies provide great 
insight in which cellular signaling pathways are activated in agonist-induced P2X7R thus it is 
reasonable to assume that enhancement or impairment of P2X7R function leads to different 
phenotype of osteoblasts. 
  
In a broader perspective these results may contribute to further understanding of the molecular basis 
of genetic variations in P2X7R and more research in this particular receptor along with other P2 
receptors is required to elucidate the mechanisms behind these variations, ultimately leading to 
identification of specific therapeutic or preventive treatments of many diseases particularly 
osteoporosis. 
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Conclusion 
 
In conclusion, we accomplished to introduce 3 specific mutations in hP2X7R inserted in pcDNA 
3.1
+
 plasmid. ROS 17/2.8 osteoblastic cells were transient transfected with these specific mutations 
to investigate the role of these mutations on P2X7R function. Data demonstrated that agonist-
induced P2X7R with R307Q SNP leads to a hypo-functional receptor while A348T SNP leads to a 
hyper-functional receptor. H155Y did not confirm a hyper-functional effect on P2X7R upon 
activation. Furthermore we demonstrated that P2X7R was expressed at mRNA level. The 
investigation of gene expression of transcription-factors and bone markers did not reveal 
unambiguous results, therefore inadequate to be conclusive.    
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